Latest Stock Buy or Sell?
Make More Informed Decisions!

It has an April year-end. They are forecasting a 10% lift in earnings. It is extremely in demand. They payout chunky dividends about once a year. He prefers others.

(A Top Pick May 18/18, Down 21%) There are concerns about restriction in western Canada about how much you can ship. There is seasonality to Nat Gas stocks and so there should be a pick-up in CNQ-T because of that. He sold last October.

(A Top Pick May 18/18, Up 8%) It continues to rank well in his work. There is good opportunity in the shipping space in North America.

(A Top Pick May 18/18, Up 17%) The industry continues to consolidate. It looks good going forward. They own dumps and needing dumps is a barrier to entry by new comers.

They struck a deal with Noramco, to sell into Canada and Mexico, synthetic CPD (for heart medication). They have enough cash to self finance the heart research.

They are struggling. In January, profit was down 79% even though sales were up 10%. Earnings estimates are expected to improve this year but still be a negative.

Their recent acquisition was a huge benefit to the company. China has said by the end of 2019 all planes must have satellite based voice communication. This is the only company that offers it. They did testing with Boeing and Airbus four months ago and passed with flying colours. This solution would have prevented the recent 737 crash having to have the flight recorder dug up from the crash site and sent to France for analysis. It's time to buy this stock.

They are producing. They are a medium sized producer. It looks like a reasonable buy but he does not follow it.

Provider of IT solutions to businesses and government. They are expected to start turning a profit during this year. He thinks there is still opportunity for it if they hit estimates for 2020.

He is a consultant to the company. The financial industry is being disrupted by fintech and this is a way to invest it in.

The outlook is still quite good. People who use their competing chronic cough treatment lose their sense of taste. They are applying now for their drug's use for other conditions.

480 times PE. Sales growth grew 45% in a recent report. He thinks there are good opportunities for overall growth.

They can maintain the dividend as well as do acquisitions. They have a 17% ROE. Near term earnings are expected to go up 10% by May. It broke out of a near term accumulation zone. He sees a 16% potential upside. (Analysts’ price target is $30.10)

Free cash flow has swung massively positive. Margins have doubled over the last year. They expect a 17% ROE. He expects a 9-19% upside. (Analysts’ price target is $47.38)

Sales were up 5%; earnings were up 26%. He expects a 14% ROE this year. If it gets above $61 it would be a potential break-out. (Analysts’ price target is $62.98)